Implementation ofMOVEMENT CONTROL ORDER (MCO)CONDITIONAL MOVEMENT CONTROL ORDER (CMCO)RECOVERY MOVEMENT CONTROL ORDER (RMCO)at NPRA
Kindly be informed National Regulatory Pharmaceutical Agency (NPRA) has resumed normal operation on premise beginning 13 May 2020.
Practice social distancing at all times and kindly be advised to physically be present on site only when necessary.
FAQ: Hand Sanitizers
FAQ: Hand Sanitizers
Cosmetics Section's compilation of Frequently Asked Questions regarding hand sanitizers.
Circular and Directive
Circular and Directive
on Covid-19 Pandemic
Official Notice for Site Inspections
Temporary Suspension for Site Inspections
Official notice for temporary suspension for inspection in and out of Malaysia for GMP, GDP, GCP and GLP and BE Research Centers.
FAQ: GMP & GDP Inspections
FAQ: GMP & GDP Inspections
FREQUENTLY ASKED QUESTIONS ON GOOD MANUFACTURING PRACTICE (GMP) AND GOOD DISTRIBUTION PRACTICE (GDP) INSPECTIONS BY NATIONAL PAHARMACEUTICAL REGULATORY AGENCY (NPRA) DURING COVID-19 PANDEMIC
FAQ: Clinical Trials
FAQ: Clinical Trial
Guidance from Evaluation and Safety of Investigational Product Section on Managing Clinical Trials during the Covid-19 Pandemic in Malaysia.
FAQ COVID-19 Vaccine
FAQ COVID-19 Vaccine
Reporting ADR (including drugs used for COVID-19 treatment)
Please report ALL suspected Adverse Drug Reactions (ADRs) to the National Centre for Adverse Drug Reactions Monitoring.
Click for more info.
